Literature DB >> 8750108

Parkinson's disease epidemiology in the Northampton District, England, 1992.

R L Sutcliffe1, J R Meara.   

Abstract

In a population of 302,000, in a Midlands district of England, the estimated prevalence of idiopathic Parkinson's disease (IPD) increased from 108 to 121 per 100,000 from 1982 to 1992. Individual general practice prevalence ranged quite widely. Webster ratings were significantly more often scored in 1992, but at a lower level of severity, suggesting earlier diagnosis. Incidence in 1992 was estimated as 12 per 100,000 per annum. Micrographia, when copying interlocking pentagons, was significantly related to Hoehn & Yahr scores. Over the 10-year period, there has been a considerable change in prescribing: a positive response to medication was confirmed as a good diagnostic indicator. Progression of symptoms and an increase of physical disability was noted in those of the 1982 study alive in 1992.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8750108     DOI: 10.1111/j.1600-0404.1995.tb00478.x

Source DB:  PubMed          Journal:  Acta Neurol Scand        ISSN: 0001-6314            Impact factor:   3.209


  9 in total

1.  Cross sectional prevalence survey of idiopathic Parkinson's disease and Parkinsonism in London.

Authors:  A Schrag; Y Ben-Shlomo; N P Quinn
Journal:  BMJ       Date:  2000-07-01

Review 2.  Health-related quality of life and healthcare utilisation in patients with Parkinson's disease: impact of motor fluctuations and dyskinesias.

Authors:  R C Dodel; K Berger; W H Oertel
Journal:  Pharmacoeconomics       Date:  2001       Impact factor: 4.981

Review 3.  Modelling the cost effectiveness of treatments for Parkinson's disease: a methodological review.

Authors:  Judith Dams; Bernhard Bornschein; Jens Peter Reese; Annette Conrads-Frank; Wolfgang H Oertel; Uwe Siebert; Richard Dodel
Journal:  Pharmacoeconomics       Date:  2011-12       Impact factor: 4.981

4.  How valid is the clinical diagnosis of Parkinson's disease in the community?

Authors:  A Schrag; Y Ben-Shlomo; N Quinn
Journal:  J Neurol Neurosurg Psychiatry       Date:  2002-11       Impact factor: 10.154

5.  Cost analysis of ropinirole versus levodopa in the treatment of Parkinson's disease.

Authors:  Michael Iskedjian; Thomas R Einarson
Journal:  Pharmacoeconomics       Date:  2003       Impact factor: 4.981

6.  Altered platelet monoamine oxidase-B activity in idiopathic Parkinson's disease.

Authors:  Maroof Husain; Rakesh Shukla; Madhu Dikshit; Pradeep K Maheshwari; Devika Nag; Rikhab C Srimal; Prahlad K Seth; Vinay K Khanna
Journal:  Neurochem Res       Date:  2009-03-04       Impact factor: 3.996

7.  Quality of life in patients with Parkinson's disease: Translation and psychometric evaluation of the Iranian version of PDQ-39.

Authors:  Marzieh Nojomi; Zahra Mostafavian; Gholam Ali Shahidi; Crispin Jenkinson
Journal:  J Res Med Sci       Date:  2010-03       Impact factor: 1.852

8.  Epidemiology of Parkinson's disease.

Authors:  Meike Kasten; Annabel Chade; Caroline M Tanner
Journal:  Handb Clin Neurol       Date:  2007

Review 9.  Systematic review of the prevalence and incidence of Parkinson's disease in Asia.

Authors:  Weerasak Muangpaisan; Hiroyuki Hori; Carol Brayne
Journal:  J Epidemiol       Date:  2009-10-03       Impact factor: 3.211

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.